HNPOLY(SZ:300630) Xin Lang Cai Jing·2026-01-22 07:26Core Viewpoint - Hainan Puli Pharmaceutical Co., Ltd. has been penalized by the Hainan Securities Regulatory Bureau for failing to disclose its 2024 annual report within the legal timeframe, resulting in a fine of 500,000 yuan and a warning [1][2]. Group 1: Administrative Penalties - The company was ordered to correct its actions and received a fine of 500,000 yuan for the late disclosure of its 2024 annual report [1]. - The then Chairman and General Manager, Fan Minhua, was fined 200,000 yuan for not fulfilling his duties [1]. - Other individuals, Luo Tongning and Zhou Mao, received warning letters for their failure to perform due diligence regarding the company's disclosure obligations [1]. Group 2: Investor Compensation - Investors who purchased shares between April 26, 2022, and April 16, 2024, and still hold them, may voluntarily register for compensation through the "Sina Investor Rights Protection Platform" [2][4]. - The specific compensation range will be determined by the court [5]. - The legal team led by lawyer Zhao Jingguo has experience in handling securities disputes and has successfully represented investors in various compensation cases [5].